Embecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.79 USD | +2.98% |
|
-1.01% | -32.44% |
05-16 | Transcript : Embecta Corp. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM | |
05-09 | Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.44% | 738M | |
-5.17% | 182B | |
-0.18% | 108B | |
-4.04% | 67.62B | |
-5.55% | 46.61B | |
+12.06% | 45.32B | |
+6.47% | 42.11B | |
+20.33% | 31.17B | |
+13.26% | 25.66B | |
-3.89% | 24.65B |
- Stock Market
- Equities
- EMBC Stock
- News Embecta Corp.
- Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump